The new generation broad spectrum enterosorbent

The new generation broad spectrum enterosorbent

Activity Start Date 01.12.2015
Advantages and Innovations: The innovative solution is in the know-how used in the manufacture of the stock blend - finely divided silica powder. Unlike the existing drug analogues, the drug has the following advantages: - High sorption capacity - 300 square meters. m / g (3 times higher in comparison to the analogues). - Depletion of intoxication, regardless of the cause: food or alcohol poisoning, allergic reaction (the analogs have selective sorption capacity). - Contributes to overcoming the pharmacological resistance of the body to other drugs.
Center name: РИЦ - Челябинская область
Comments Regarding IPR Status: Russian Federation: 1992, 2003, 2006, 2015
Copyright: Patents granted
Current Stage of Development: CE-marking is needed
Date of creation: 01.12.2015
Description of the offer: The Russian pharmaceutical company from Chelyabinsk specializes in the research, development and production of medicinal drugs. The company has developed a new generation broad-spectrum oral enterosorbent. Currently, non-selective sorbents are the drugs of choice in the treatment of toxic food infections and poisoning of different etiologies. Therefore, the basic effectiveness parameters of their usage are the sorption capacity and safety of the body (the level of absorption into the blood, the degree of body demedication). Existing medicinal drugs have little sorption effect, selectivity towards the toxins and their use is limited to the treatment of toxic food infections and diarrheal disorders. The proposed drug is a polyfunctional enterosorbent based on highly dispersed silica having with the particle sizes up to 0.09 mm. The drug dosage form is powder. The drug is taken orally in the form of an aqueous suspension, the dosage depends on the body weight. Passing through the gastrointestinal tract, the drug adsorbs toxins, allergens, radionuclides, alcohol decomposition products, microorganisms and other substances responsible for the occurrence of various diseases. Since the initial development, the drug formula has been optimized. Currently, the spectrum of action of the drug has been enhanced, as confirmed by the patent of the possibilities of its usage: - adaptogen (1992 patent); -antioxidant, membrane stabiliser (2003 patent); - blocker of the alcohol withdrawal syndrome (2006 patent). - antiallergical drug with the detoxification mechanism of action foe dermatoses treatment (2015 patent); Also, the drug is registered throughout the European Union in accordance with the requirements of ISO 13485: 2012 and the European directive MDD 93/42 / EEC. Advantages of the drug compared to the analogues: - High sorption capacity - 300 square meters. m / g (3 times higher); - Intact withdrawal from the body; - No absorption into the blood. Partners for the manufacturing agreement and services agreement are sought. Under the manufacturing agreement the partner's tasks are to develop the design and approve manufacture of the drug package according to EU ecological requirements. Under the services agreement the partner will be provide the certification of the drug in the EU. All terms of delivery and contract will be discussed after the first contact.
Market Keywords: 05005001 Allergy research / 05005004 Gastroenterology
Profile type: Technology offer
Restrict Dissemination to specific countries: CIS Countries / Armenia / Belarus / Moldova / Ukraine / EEN Countries / Austria / Belgium / Bosnia and Herzegovina / Bulgaria / Chile / China / Egypt / Iceland / Israel / Japan / Macedonia, The former Yugoslav Republic of / Mexico / Montenegro / Norway / South Korea / Switzerland / Syria / Tunisia / Turkey / USA / Albania / Argentina / Brazil / Canada / Georgia / India / Country_Indonesia / Jordan / New Zealand / Paraguay / Peru / Russian Federation / Serbia / Singapore / Taiwan / EU Countries / Croatia / Cyprus / Czech Republic / Denmark / Estonia / Finland / France / Germany / Greece / Hungary / Ireland / Italy / Latvia / Lithuania / Luxembourg / Malta / Netherlands / Poland / Portugal / Romania / Slovakia / Slovenia / Spain / Sweden / United Kingdom
Summary: The Russian pharmaceutical company from Chelyabinsk, which specializes in the production of medicinal drugs, developed a broad spectrum enterosorbent of the new generation. The drug is used for intoxication of various origins (including alcohol), gastrointestinal infections, allergies, disbacteriosis. The company is looking for the partners under the manufacturing agreement and services agreement.
Technological Keywords: 06001015 Pharmaceutical Products / Drugs
Type and Role of Partner Sought: Type of partner: SME, R&D. Field of activity: medicine and pharmaceutics, product certification. Partner's role: product certification in EU, design and manufacture of the drug package according to EU ecological standards.
Type of Partnership Required: Manufacturing Agreement / Services Agreement

Back to the list

logo Республиканский фонд поддержки малого и среднего предпринимательства
logo Бизнес-инкубатор РМЭ
logo Торгово-промышленная палата РМЭ
logo Инвестиционный портал РМЭ